Trial Profile
Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Apr 2022
Price :
$35
*
At a glance
- Drugs Rabeprazole (Primary) ; Ranitidine
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 06 Sep 2009 New trial record